Source comparison
Thymosin Alpha-1 Oral vs Injectable: Side-by-Side Comparison
The table below compares thymosin alpha-1 oral and injectable administration across key parameters relevant to research protocol design and expected outcomes. Bioavailability 90–95% (direct systemic entry) <5% (gastric/enzymatic degradation) Only injectable ac
This comparison does not assign a generated winner or score.
- The table below compares thymosin alpha-1 oral and injectable administration across key parameters relevant to research protocol design and expected outcomes.
- Bioavailability
- 90–95% (direct systemic entry)
- <5% (gastric/enzymatic degradation)
- Only injectable achieves therapeutic serum levels
- Injectable is the only validated route
- Peak Plasma Concentration (Cmax)
- 50–150 ng/mL at 1.6mg dose
- Undetectable (<50 pg/mL)
- Oral forms do not reach receptor-binding threshold
- Oral administration produces no measurable serum peptide
- Mechanism Access
- Direct receptor binding on immune cells
- No receptor access (peptide degraded pre-absorption)
- Mechanism of action requires systemic circulation
- Oral peptides cannot engage target receptors
- Peer-Reviewed Evidence
- 18+ RCTs in hepatitis B, cancer, sepsis
- Zero RCTs demonstrating clinical endpoints
- Evidence base exists only for injectable form
- No credible clinical data supports oral thymosin alpha-1
- Dosing Schedule
- 1.6mg twice weekly (standard protocol)
- Varies widely (10–100mg daily claimed)
- Oral doses are arbitrary due to lack of absorption
- Injectable protocols are evidence-based and reproducible
- Storage Requirements
- −20°C lyophilised; 2–8°C reconstituted
- Room temperature (enteric-coated)
- Temperature control critical for peptide stability
- Injectable demands cold chain; oral stability is irrelevant if peptide is inactive
- Administration Complexity
- Subcutaneous injection (trained technique required)
- Oral ingestion (no preparation needed)
- Injectable requires protocol training but guarantees delivery
- Convenience of oral route does not compensate for inefficacy
- Regulatory Classification
- Research peptide (not FDA-approved drug)
- Dietary supplement (minimal oversight)
- Neither is approved for human therapeutic use, but only injectable has clinical data
- Injectable peptides are research tools with defined pharmacokinetics